Tetra Pharm Technologies, Kvantify Partner to Accelerate Discovery of Novel Drug Candidates

Tetra Pharm Technologies and Kvantify have partnered to accelerate the identification and development of novel drug candidates targeting the endocannabinoid system (ECS).
 
“This partnership will expedite our drug development process and significantly expand our pipeline of promising drug candidates in 2024,” says Martin Rose, CEO of Tetra Pharm Technologies.
 
The partnership’s aim is to transform the landscape of ECS-targeted drug discovery, potentially leading to significant advancements in therapeutic options for patients.
 
Together, the partners will explore the complexities of endocannabinoid receptors and their interactions with potential drug candidates from Tetra Pharm Technologies’ pipeline. This approach is expected to not only advance the existing pipeline significantly but also lead to new discoveries within the field.
 
At this point, Tetra Pharm Technologies has 11 drug candidates in its pipeline, each targeting specific receptors with distinct modes of action and more candidates on their way. For each pipeline candidate Tetra Pharm Technologies pursues a distinct mode of action at the receptor level based on their scientists’ understanding of the endocannabinoid system; that is, which receptors they wish to hit, and – equally important – which receptors to be avoided in terms of side effect profile.
 
“The Kvantify platform enables us to screen much broader and to more effectively identify key structural attributes of our drug candidates to guide our in-vitro cellular pharmacology and ultimately our CMC activities. Since the potential formulation hassles have already been mitigated with our proprietary drug delivery system, we can undoubtedly progress candidates even faster through our pipeline,” says Dr. Morten Allesø, Chief Scientific Officer at Tetra Pharm Technologies.
 
The collaboration involves a comprehensive screening of nearly 1,000 molecular combinations suspected of acting as ligands to endocannabinoid receptors. This screening is conducted using Kvantify’s CNS module, providing Tetra Pharm Technologies additional insight into the propensity for blood-brain-barrier penetration.
 
Nils Anton Berglund, Head of Strategic Alliances at Kvantify, explains: “With Tetra Pharm Technologies’ deep knowledge of the endocannabinoid biology and the atomistic level precision that Kvantify’s CNS drug discovery platform can deliver, we believe the collaboration can uncover ground-breaking new science for the benefit of patients around the globe.”
 
Hans Henrik Knudsen, CEO at Kvantify, says, “The combination of Tetra Pharm Technologies’ novel drug delivery technology with Kvantify’s computational drug discovery platform, makes for an incredibly exciting synergy that will facilitate more rapid and efficient development of novel drugs.”